Annual report pursuant to Section 13 and 15(d)

Collaborative, Licensing and Other Arrangements - Novo Nordisk - Additional Information (Details)

v3.3.1.900
Collaborative, Licensing and Other Arrangements - Novo Nordisk - Additional Information (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2015
Dec. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Performance deliverable period for license and transfer of technology and knowhow   60 days
Upfront payment recognized as revenue   $ 5,000,000
Novo Nordisk [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Upfront payment received $ 5,000,000  
Agreement termination notice period   90 days
Collaborative Arrangement [Member] | Novo Nordisk [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Upfront payment received   $ 5,000,000
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones   290,000,000
Milestone received under the collaboration agreement   $ 0